Clinical Management of Psychostimulant Withdrawal: Review of the Evidence

Lit review
par
Li, Michael J. & Steven J. Shoptaw

Date de publication

2022

Géographie

USA

Langue de la ressource

English

Texte disponible en version intégrale

Non

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

This review of clinical research reports the evidence regarding biomedical and behavioral treatments for psychostimulant withdrawal symptoms.

Constatations/points à retenir

Potential efficacy for MA withdrawal is noted for a few medications (mirtazapine, naltrexone, bupropion) and repetitive transcranial magnetic stimulation during acute (first week), early protracted (weeks 2-4) and late protracted (>4 weeks) withdrawal phases. Topiramate shows mixed evidence of efficacy for cocaine withdrawal. In general, there is inconsistent signal for biomedical and behavioral treatments on MA and cocaine withdrawal.

Mots clés

Withdrawal
Stimulants
Clinical guidance